HOOKIPA PHARMA INC (HOOK) Stock Price, Forecast & Analysis
USA - NASDAQ:HOOK - US43906K2096 - Common Stock
HOOK Key Statistics, Chart & Performance
The current stock price of HOOK is 0.8403 USD. In the past month the price decreased by -31.68%. In the past year, price decreased by -82.12%.
HOOK Latest News, Press Relases and Analysis
HOOK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| ARGX | ARGENX SE - ADR | 63.46 | 52.40B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.37 | 36.51B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B |
Related stock screener links
About HOOK
Company Profile
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Company Info
HOOKIPA PHARMA INC
350 Fifth Avenue, 72Nd Floor, Suite 7240
New York City NEW YORK 10118 US
CEO: Joern Aldag
Employees: 82
Phone: 114318906360
HOOKIPA PHARMA INC / HOOK FAQ
What does HOOKIPA PHARMA INC do?
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
What is the current price of HOOK stock?
The current stock price of HOOK is 0.8403 USD. The price decreased by -6.92% in the last trading session.
Does HOOK stock pay dividends?
HOOK does not pay a dividend.
How is the ChartMill rating for HOOKIPA PHARMA INC?
HOOK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does HOOKIPA PHARMA INC belong to?
HOOKIPA PHARMA INC (HOOK) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of HOOKIPA PHARMA INC (HOOK)?
You can find the ownership structure of HOOKIPA PHARMA INC (HOOK) on the Ownership tab.
HOOK Technical Analysis
HOOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HOOK. While HOOK has a great health rating, there are worries on its profitability.
HOOK Financial Highlights
Over the last trailing twelve months HOOK reported a non-GAAP Earnings per Share(EPS) of -5.84. The EPS decreased by -16.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.68% | ||
| ROE | -215.12% | ||
| Debt/Equity | 0 |
HOOK Forecast & Estimates
7 analysts have analysed HOOK and the average price target is 29.07 USD. This implies a price increase of 3359.48% is expected in the next year compared to the current price of 0.8403.
For the next year, analysts expect an EPS growth of 24.44% and a revenue growth -49.08% for HOOK